期刊
CELLULAR AND MOLECULAR LIFE SCIENCES
卷 68, 期 24, 页码 4101-4114出版社
SPRINGER BASEL AG
DOI: 10.1007/s00018-011-0727-1
关键词
Cardiomyocyte; DNA double-strand break; gamma H2AX; Cardiotoxicity; Doxorubicin; Histone deacetylase inhibitor; Trichostatin A; Valproic acid; Sodium butyrate
资金
- Australian Institute of Nuclear Science and Engineering (AINSE)
- National Health and Medical Research Council (NHMRC)
- CRC for Biomedical Imaging Development (CRC-BID)
Histone deacetylase inhibitors have emerged as a new class of anticancer therapeutics with suberoylanilide hydroxamic acid (Vorinostat) and depsipeptide (Romidepsin) already being approved for clinical use. Numerous studies have identified that histone deacetylase inhibitors will be most effective in the clinic when used in combination with conventional cancer therapies such as ionizing radiation and chemotherapeutic agents. One promising combination, particularly for hematologic malignancies, involves the use of histone deacetylase inhibitors with the anthracycline, doxorubicin. However, we previously identified that trichostatin A can potentiate doxorubicin-induced hypertrophy, the dose-limiting side-effect of the anthracycline, in cardiac myocytes. Here we have the extended the earlier studies and evaluated the effects of combinations of the histone deacetylase inhibitors, trichostatin A, valproic acid and sodium butyrate on doxorubicin-induced DNA double-strand breaks in cardiomyocytes. Using gamma H2AX as a molecular marker for the DNA lesions, we identified that all of the broad-spectrum histone deacetylase inhibitors tested augment doxorubicin-induced DNA damage. Furthermore, it is evident from the fluorescence photomicrographs of stained nuclei that the histone deacetylase inhibitors also augment doxorubicin-induced hypertrophy. These observations highlight the importance of investigating potential side-effects, in relevant model systems, which may be associated with emerging combination therapies for cancer.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据